Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.63 | N/A | +25.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.63 | N/A | +25.27% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, highlighting advancements in their pipeline. They maintained a cautious but positive outlook.
We are pleased with our progress in the quarter.
Our focus remains on advancing our pipeline.
Revolution Medicines reported a narrower-than-expected loss per share, which contributed to a slight increase in their stock price. The positive surprise in EPS indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data and forward guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHART INDS INC
Feb 24, 2023